Browse
Submit Data
Databases
API
Help

Dataset Information

46 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Stool-based SDC2 DNA Methylation Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer

ABSTRACT: The primary objective is to compare the performance of Stool-based SDC2 DNA Methylation Test and commercially available Fecal Immunochemical Test(FIT) , on the detection rate of advanced adenomatous polyps and colorectal cancer in Chinese population. Subjects with positive results in either test will receive colonoscopy. Lesions will be confirmed as malignant or precancerous by colonoscopy and histopathologic examination.

DISEASE(S): Adenomatous Polyps,Screening,Colorectal Cancer,Colorectal Neoplasms,Colorectal Adenomatous Polyp,Polyps

PROVIDER: 2326441 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Colorectal Cancer Screening Using Stool DNA-based SDC2 and SFRP2 Methylation Test in China

Project description:The primary objective is to determine sensitivity, specificity, positive predictive value and negative predictive value of a bi-target stool DNA testing (the methylation status of SDC2 and SFRP2) for colorectal cancer and advanced precancerous neoplasm(including advanced adenoma and advanced serrated lesions) screening, using colonoscopy as the reference method. Lesions will be confirmed as malignant or precancerous by histopathologic examination. The secondary objective is to compare the performance of the bi-target stool DNA testing to a commercially available fecal immunochemical test (FIT) assay, both with respect to cancer and advanced precancerous neoplasm. Lesions will be confirmed as malignant or precancerous by colonoscopy and histopathologic examination.

| 2348965 | ecrin-mdr-crc

A Stool DNA-based SDC2 Methylation Test for the Early Detection of Colorectal Cancer

Project description:The primary objective of this clinical trial is to determine the sensitivity and specificity of the EarlyTect CRC test for detecting CRC, using colonoscopy as the reference method. The secondary objective is to compare the clinical performance of EarlyTect CRC test with a commercially available Fecal Immunochemical Test (FIT), with respect to CRC. By histopathological examination, lesions identified during colonoscopy will be confirmed as malignant or precancerous by histological examination.

| 2405892 | ecrin-mdr-crc

Multiple Screening Methods for the Detection of Chinese Colorectal Advanced Adenomatous Polyps and Cancer

Project description:The primary objective is to determine the sensitivity and specificity of two Colorectal Cancer (CRC) screening methods, including stool DNA test and blood mRNA test, for colorectal cancer in Chinese population, with colonoscopy as reference method. Lesions will be confirmed as malignant or precancerous by colonoscopy and histopathologic examination. The secondary objective is to compare the performance of these two CRC screening methods to a commercially available FIT assay, both with respect to cancer and advanced adenoma. Lesions will be confirmed as malignant or precancerous by colonoscopy and histopathologic examination.

| 2264226 | ecrin-mdr-crc

Colorectal Cancer Screening Using Stool DNA-based SDC2 Methylation Test

Project description:A study of colorectal cancer screening using stool DNA-based SDC2 methylation test

| 2332763 | ecrin-mdr-crc

Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer

Project description:The primary objective is to determine the sensitivity and specificity of the Exact Colorectal Cancer (CRC) screening test for colorectal cancer, using colonoscopy as the reference method. Lesions will be confirmed as malignant by histopathologic examination. The secondary objective is to compare the performance of the Exact CRC screening test to a commercially available FIT assay, both with respect to cancer and advanced adenoma. Lesions will be confirmed as malignant or precancerous by colonoscopy and histopathologic examination.

| 2110030 | ecrin-mdr-crc

Clinical Validation of Stool DNA-based SDC2 Methylation Test for Colorectal Cancer Detection

Project description:Pivotal trials of SDC2 methylation biomarker test in stool DNA to estimate clinical sensitivity and specificity in detection of colorectal cancer.

| 2243869 | ecrin-mdr-crc

Clinical study of fecal SDC2 / TFPI2 methylation combined with FIT in the detection of colorectal cancer and precancerous lesions

Project description:Interventions: Gold Standard:colonoscopy/pathological diagnosis;Index test:fecal SDC2 / TFPI2 methylation combined with FIT Primary outcome(s): fecal SDC2 / TFPI2 methylation;stool occult blood test;colonoscopic results;pathologic results Study Design: Factorial

| 2725740 | ecrin-mdr-crc

Multi-center Clinical Trial of Methylation Detection Kit for SDC2 Gene (Real Time PCR) (Product Name: ColoSafe)

Project description:Interventions: Gold Standard:colonoscopy, Pathological examination;Index test:Methylation Detection Kit for SDC2 Gene (Real Time PCR)(Product Name: ColoSafe) Primary outcome(s): Sensitivity;Specificity;ACC;Kappa Study Design: Sequential

| 2687377 | ecrin-mdr-crc

A clinical trials based on SDC2/NDRG4 Gene Methylation Detection Kit (PCR-Fluorescence Probe Method) in vitro diagnostic reagent kit used to qualitative detection of human colorectal cancer genes based on their methylation status.

Project description:Interventions: Gold Standard:Colonoscopy, Pathological biopsy;Index test:Feces, SDC2/NDRG4 Gene Methylation Detection Kit Primary outcome(s): Sensitivity of the Kit in the diagnosis of colorectal cancer;Specificity of the Kit in the diagnosis of colorectal cancer Study Design: Diagnostic test for accuracy

| 113468 | ecrin-mdr-crc

Evolution of immune and stromal cell states and ecotypes during gastric adenocarcinoma progression

Project description:Understanding how the tumor microenvironment (TME) is orchestrated along the continuum of gastric adenocarcinoma (GAC) may uncover novel therapeutic strategies. Here, we performed comprehensive single-cell profiling of precancerous lesions, localized and metastatic GACs, identifying alterations in TME cell states and phenotypes during tumorigenesis and progression. IgA+ plasma cells appear to be the most active regulators in the premalignant microenvironment, whereas immunosuppressive myeloid and stromal subsets dominated the late-stage GACs. We discover six TME ecotypes, four of which are unique to the premalignant/progression in the continuum, with two ecotypes, identified in primary GACs, showing strong associations with histopathologic, genomic characteristics and prognosis. Extensive stromal remodeling is evident with GAC progression. High SDC2 expression in cancer-associated fibroblasts (CAFs) correlates with aggressive phenotypes and poor survival and SDC2 overexpression in CAFs contributes to tumor growth. This study illustrates a roadmap of the GAC TME and highlights potential targets for further investigation.

2023-06-10 | GSE234129 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data